- Home
- IONS vs IDA Comparison
IONS vs IDA Comparison
Compare IONS & IDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- IDA
- Stock Information
- Founded
- IONS 1989
- IDA 1915
- Country
- IONS United States
- IDA United States
- Employees
- IONS N/A
- IDA 2112
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- IDA Electric Utilities: Central
- Sector
- IONS Health Care
- IDA Utilities
- Exchange
- IONS Nasdaq
- IDA Nasdaq
- Market Cap
- IONS 6.0B
- IDA 6.1B
- IPO Year
- IONS 1991
- IDA N/A
- Fundamental
- Price
- IONS $32.32
- IDA $114.14
- Analyst Decision
- IONS Buy
- IDA Buy
- Analyst Count
- IONS 19
- IDA 5
- Target Price
- IONS $61.24
- IDA $116.20
- AVG Volume (30 Days)
- IONS 1.7M
- IDA 277.3K
- Earning Date
- IONS 02-19-2025
- IDA 02-20-2025
- Dividend Yield
- IONS N/A
- IDA 3.02%
- EPS Growth
- IONS N/A
- IDA 7.00
- EPS
- IONS N/A
- IDA 5.50
- Revenue
- IONS $705,000,000.00
- IDA $1,826,633,000.00
- Revenue This Year
- IONS N/A
- IDA $5.13
- Revenue Next Year
- IONS $10.08
- IDA $5.98
- P/E Ratio
- IONS N/A
- IDA $20.71
- Revenue Growth
- IONS N/A
- IDA 3.41
- 52 Week Low
- IONS $30.23
- IDA $86.47
- 52 Week High
- IONS $52.34
- IDA $120.42
- Technical
- Relative Strength Index (RSI)
- IONS 48.36
- IDA 64.86
- Support Level
- IONS $30.86
- IDA $109.55
- Resistance Level
- IONS $34.74
- IDA $111.66
- Average True Range (ATR)
- IONS 1.35
- IDA 1.93
- MACD
- IONS 0.18
- IDA 0.35
- Stochastic Oscillator
- IONS 46.34
- IDA 84.69
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About IDA IDACORP Inc.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. To do this, Idacorp owns and operates a portfolio of hydroelectric, coal-fired, gas-fired, and diesel-fired power plants located across the Northwestern United States. The company's hydroelectric and coal-fired plants are responsible for Majority of its total energy production. Idacorp mainly generates revenue from the sale of electricity to retail and wholesale customers. The Majority of the company's customers are residential consumers living in the Northwestern United States, while commercial and industrial consumers also represent important revenue streams.